The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- MHLW Revises Notifications on Electronic Data Submission as End of Grace Period Approaches
January 28, 2019
- Resistant Virus Found in Kids Administered Xofluza: NIID
January 28, 2019
- NITE, Genome Pharmaceuticals Institute Jointly Explore Rare Actinomycetes for MRSA
January 28, 2019
- “Detailed Discussions” Necessary for Use of Real World Data: HSC Panel
January 25, 2019
- MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
- Maviret, Ibrance, PD-1 Inhibitors under PMDA Risk Review
January 21, 2019
- MHLW to Give Enough Preparation Time for Local Govts before New PMD Law Takes Effect
January 21, 2019
- Iron Deficiency Med Ferinject Up for MHLW Panel Review on Jan. 31; No Vyvanse Discussion This Time
January 18, 2019
- MHLW Panels Find No Major Safety Concern for 14 Vaccines: July-October
January 17, 2019
- Nearly 1 Million People Newly Diagnosed with Cancer in Japan in 2016: MHLW
January 17, 2019
- Janssen’s Xtandi Rival Up for MHLW Panel Review on Jan. 30; Enbrel Biosimilars Also on Agenda
January 17, 2019
- PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan
January 17, 2019
- PMDA to Raise Its Service Fees, Up 28% for New Drug Reviews; MHLW Invites Public Opinions
January 17, 2019
- Chuikyo OKs Pricing Rule Revision for October Re-Pricing; Stemirac to Be Priced as Medicine
January 16, 2019
- MHLW Won’t Necessarily Push March Announcement of New Drug Prices: Bureau Head
January 16, 2019
- PMDA to Raise Fees and Expand Workforce to Boost Review and Safety Measures, GMP Inspection
January 15, 2019
- MHLW Panel OKs 5-Year Extension of Pneumovax Transitional Measure
January 11, 2019
- MHLW Orders Label Revisions for Inlyta, Spinraza, and More
January 11, 2019
- New NHI Prices Will Be Announced “at Most Appropriate Time”: MHLW Official
January 10, 2019
- MHLW to Revise Biosimilar Guidelines to Increase Efficiency in Development, Review; Final Draft Expected in FY2019
January 10, 2019
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…